Morgan Stanley’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-4
Closed -$195 – 7925
2023
Q3
$195 Sell
4
-2
-33% -$141 ﹤0.01% 7389
2023
Q2
$484 Hold
6
– – ﹤0.01% 7379
2023
Q1
$482 Sell
6
-38
-86% -$3.51K ﹤0.01% 7442
2022
Q4
$3.86K Buy
44
+24
+120% +$4.35K ﹤0.01% 7218
2022
Q3
$15K Buy
+20
New +$6.4K ﹤0.01% 6932
2022
Q2
– Sell
-1
Closed – – 8029
2022
Q1
$0 Buy
+1
New +$747 ﹤0.01% 8161
2021
Q4
– Hold
0
– – – 8142
2021
Q3
– Hold
0
– – – 8051
2021
Q2
– Hold
0
– – – 7823
2021
Q1
– Sell
-22
Closed -$151K – 7588
2020
Q4
$149K Buy
22
+2
+10% +$10.5K ﹤0.01% 5738
2020
Q3
$246K Buy
20
+15
+300% +$182K ﹤0.01% 5002
2020
Q2
$66K Buy
5
+1
+25% +$11.3K ﹤0.01% 5576
2020
Q1
$42K Buy
4
+1
+33% +$10K ﹤0.01% 5536
2019
Q4
$31K Buy
3
+2
+200% +$14K ﹤0.01% 5991
2019
Q3
$7K Buy
+1
New +$6.81K ﹤0.01% 6305
2018
Q2
– Hold
0
– – – 6770
2018
Q1
– Hold
0
– – – 6718
2017
Q4
– Sell
-1
Closed -$5.1K – 6672
2017
Q3
$4K Buy
+1
New +$7.34K ﹤0.01% 6332

Other funds holding ATXI

Morgan Stanley's ATXI Position: Q4 2023 in Review

Morgan Stanley sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2023, closing a stake of 4 shares — an estimated $195 sold.

Morgan Stanley first reported a position in ATXI in Q3 2017 and held it in 13 quarters. The position peaked at $246K in Q3 2020. 14 funds tracked by Wall St. Rank hold ATXI as of Q4 2023.

  • Morgan Stanley reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 4 Avenue Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $195.
  • Morgan Stanley first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Morgan Stanley's Avenue Therapeutics, Inc. Common Stock position peaked at $246K in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.